INmune Bio Inc
INMB
NASDAQ
Biotechnology
$2.17
USD
+0.09 (+4.33%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $58.56M
Volume 461.4K
Revenue
$0
TTM
-100.0%
YoY
Gross Margin
—
TTM
— YoY
Net Income
$-18.42M
TTM
+66.8%
YoY
Operating Cash Flow
$-14.96M
TTM
+53.5%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | -100.0% | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 2.3 | 2.5 | 3.1 | 2.2 | 2.3 |
Other Operating Expenses | 16.5 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 24.6 | 7.4 | 5.5 | 5.8 | 1.5 |
Operating Income | -24.6 | -7.4 | -5.5 | -5.8 | -1.5 |
EBITDA | -8.1 | -7.4 | -5.4 | -5.8 | -1.4 |
Other Income / Expense | 0.1 | 1.0 | 0.2 | 0.4 | 0.2 |
Total Other Income / Expense | 0.1 | 1.0 | 0.2 | 0.4 | 0.2 |
Income Before Income Taxes | -24.5 | -6.5 | -5.3 | -5.4 | -1.3 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -24.5 | -6.5 | -5.3 | -5.4 | -1.3 |
Consolidated Net Income / Loss | -24.5 | -6.5 | -5.3 | -5.4 | -1.3 |
Net Income Attributable to Common Shareholders | -24.5 | -6.5 | -5.3 | -5.4 | -1.3 |
Basic EPS | -$1.05 | -$0.24 | -$0.20 | -$0.20 | -$0.05 |
Diluted EPS | -$1.05 | -$0.24 | -$0.20 | -$0.20 | -$0.05 |
Basic Shares Outstanding | 23.3M | 26.6M | 26.7M | 26.6M | 26.7M |
Diluted Shares Outstanding | 23.3M | 26.6M | 26.7M | 26.6M | 26.7M |